Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

Lymphoma Clinical Trial

Official title:

Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00035022
• Other study ID #: BC-01-02
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: May 2, 2002
• Last updated: January 12, 2006
• Start date: August 2001
• Est. completion date: March 2004

Study information

• Verified date: February 2005
• Source: BioCryst Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.

Description:

Despite the great strides that have been made in improving the outcome with frontline programs of intensive chemotherapy in patients with aggressive T-cell malignancies, the prognosis with relapsed or refractory T-cell leukemias or lymphomas is poor. BCX-1777 is a purine nucleoside phosphorylase (PNP) inhibitor and a potential T-cell target therapy.

The purpose of the phase I portion of the study is to determine the maximum tolerated dose (MTD) of BCX-1777 and the dose to be studied in the phase II portion of the study.

The purpose of the phase II portion of the study is to determine the safety and efficacy of BCX-1777 in patients with relapsed or refractory aggressive T-cell malignancies.

Patients who respond to BCX-1777 or have stable disease may be eligible to receive an additional course of treatment.

Other known NCT identifiers

• NCT00066235

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: March 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Previously treated, relapsed or refractory aggressive T-cell malignancies (leukemias and lymphomas) histologically proven with measurable disease.

• Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.

• All ages are eligible. Pediatric patients (<15 years of age) are eligible to be treated at a dose level previously tested in adults.

• Adequate liver and renal function.

• Patients with prior history of stem cell transplant if they meet all other eligibility requirements.

• Negative pregnancy test within 72 hours of study treatment in females of childbearing potential.

• Life expectancy of at least 2 months.

Exclusion:

• Active serious infection not controlled by oral or intravenous antibiotics.

• Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side-effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.

• Concurrent treatment with other anti-cancer agents.

• Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy. Lumbar puncture not required in asymptomatic patients.

• Pregnant and/or lactating women; or fertile men or women not willing to use contraception.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia, Lymphocytic
• Leukemia, Lymphoid
• Lymphoma

Intervention

Drug:
• BCX-1777

Locations

Country	Name	City	State
United States	M.D. Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
BioCryst Pharmaceuticals

Country where clinical trial is conducted

United States,